A rapid and specific assay for the determination of lamotrigine in human plasma by normal-phase HPLC

Therapeutic Drug Monitoring

Volumn 19, Issue 1, 1997, Pages 100-107

  Bartoli, Anna ^a   Marchiselli, Roberto ^a   Gatti, Giuliana ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Drug assay; High performance liquid chromatography; Lamotrigine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; VIGABATRIN;

ARTICLE; DRUG DETERMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; RELIABILITY;

ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRIAZINES;

EID: 0031427880     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199702000-00020     Document Type: Article

References (31)

1. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-400.
2. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46:152-76.
3. Messenheimer JA. Lamotrigine. Clin Neuropharmacol 1994;17: 548-59.
4. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
5. Binnie CD, Debets RMC, Englesman M, et al. Double-blind crossover trial of lamotrigine (lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989;4:222-9.
6. Sanders JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6: 221-6.
7. Loiseau P, Yuen AWC, Duche B, Menager T, Arnebes MC. A randomized double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45.
8. Pellock JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994;44(suppl 8):S29-35.
9. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
10. Pisani F, Russo M, Trio R, et al. Lamotrigine-valproate comedication in refractory partial seizures: a report of six cases. Epilepsia 1993;34(suppl 2):159.
11. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamotrigine: single dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
12. Ramsay RE, Pellock JM, et al. Pharmacokinetics and safety of lamotrigine (lamictal) in patients with epilepsy. Epilepsy Res 1991; 10:191-200.
13. Yuen AWC, Land G, Weatherly BC, Peck AW. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33: 511-3.
14. Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy 1992;5:73-9.
15. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-43.
16. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
17. Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 1991;32(suppl 2):S17-21.
18. Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 1993;342:185-6.
19. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
20. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinemia (Gilbert's syndrome). Br J Clin Pharmacol 1989;28:117-20.
21. Sinz MW, Remmel RP. Analysis of lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reversed-phase ion-pairing liquid chromatography. J Chromatogr 1991;571:217-30.
22. Cociglio M, Alric R, Bouvier O. Performance analysis of a reversed phase liquid chromatographic assay of lamotrigine using solvent demixing extraction. J Chromatogr 1991;572:269-76.
23. Fazio A, Artesi C, Russo M, Trio R, Oteri G, Pisani F. A liquid chromatographic assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug in human plasma. Ther Drug Monit 1992;14:509-12.
24. Ramachandran S, Underhill S, Jones SR. Measurement of lamotrigine under conditions measuring phenobarbitone, phenytoin and carbamazepine using reversed-phase high-performance liquid chromatography at dual wavelengths. Ther Drug Monit 1994;16: 75-82.
25. Fraser AD, MacNeil W, Isner AF, Camfield PR. Lamotrigine analysis in serum by high-performance liquid chromatography. Ther Drug Monit 1995;17/2:174-8.
26. Meyler M, Kelly MT, Smyth MR. New method for the determination of four antiepileptic drugs in human plasma by high performance liquid chromatography. Chromatographia 1993;36:27-32.
27. Boutagy J, Dell Anna M. Simplified and rapid HPLC procedure for analysis of lamotrigine in plasma. Ther Drug Monit 1995;17:410.
28. Svensson JO. Simple HPLC method for determination of antiepileptic drugs in plasma. Ther Drug Monit 1995;17:408.
29. Juergens U. Alkylamine phosporic acid as a universal buffer system for basic and acidic mobile phases in HPLC. J Liq Chromatogr 1988;11:1925-40.
30. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharmaceut Sci 1992;81:309-12.
31. Hundt HKL, Aucamp AK, Muller FO, Potgieter MA. Carbamazepine and its major metabolites in plasma: a summary of eight years of therapeutic drug monitoring. Ther Drug Monit 1983;5: 427-35.